Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.

RPEP-071592023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Published In:
International immunopharmacology, 117, 109952 (2023)
Authors:
Mao, Li
Database ID:
RPEP-07159

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-07159·https://rethinkpeptides.com/research/RPEP-07159

APA

Mao, Li. (2023). Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.. International immunopharmacology, 117, 109952. https://doi.org/10.1016/j.intimp.2023.109952

MLA

Mao, Li. "Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.." International immunopharmacology, 2023. https://doi.org/10.1016/j.intimp.2023.109952

RethinkPeptides

RethinkPeptides Research Database. "Thymosin alpha 1 - Reimagine its broader applications in the..." RPEP-07159. Retrieved from https://rethinkpeptides.com/research/mao-2023-thymosin-alpha-1-reimagine

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.